Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 1 Jan 2007

Al-Batran Salah-Eddin, Hartmann Joerg Thomas, Heidel Florian, Stoehlmacher Jan, Wardelmann Eva, Dechow Claudius, Düx Markus, Izbicki Jacob Robert, Kraus Thomas, Fischer Thomas, Jäger Elke

Abstract excerpt

BACKGROUND: This study aimed to investigate the outcome of patients with advanced gastrointestinal stromal tumors (GISTs) exhibiting focal disease progression during imatinib therapy, treated by surgical resection and imatinib continuation. METHODS: A consecutive series of 38 patients with metastatic GISTs who underwent treatment with imatinib at our centers during a defined period of time was evaluated. Patients...

Topics

Join the communities discussing this publication.

Benzamides
Disease-Free Survival
Gastrointestinal Stromal Tumors
Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Proto-Oncogene Proteins c-kit

Salvage Therapy

Source

Identifiers

PMID: 17922091
DOI: 10.1007/s10120-007-0425-8

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.PMID 17922091Read ↗

Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.Semantic proximity Read ↗

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).Semantic proximity Read ↗

Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.Semantic proximity Read ↗

Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.Semantic proximity Read ↗

Gastrointestinal stromal tumor after tyrosine kinase inhibition therapy: a review of biopsies of 34 patients with clinically suspected relapse and/or progression of the tumor.Semantic proximity Read ↗

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment.Semantic proximity Read ↗

Local treatment in metastatic GIST patients: A multicentre analysis from the Dutch GIST Registry.Semantic proximity Read ↗

Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.Semantic proximity Read ↗

A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.Semantic proximity Read ↗

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.Semantic proximity Read ↗

Metabolic pseudo-progression in a patient with metastatic KIT exon 11 GIST after one month of first-line imatinib: a case reportSemantic proximity Read ↗

Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.